Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PDE inhibitor
Roflumilast acts as a selective, long-acting inhibitor of the enzyme PDE-4.- Bo Liao, .et al. , Exp Ther Med, 2023, May 9;25(6):302 PMID: 37229319
- Zhongyuan Zhang, .et al. , Exp Ther Med, 2021, Dec;22(6):1398 PMID: 34650646
- Bing Zhong, .et al. , ACS Omega, 2021, Jan 26; 6(3): 2149-2155 PMID: 33521454
-
PDE-4 inhibitor
Cilomilast is orally active and acts as a selective Phosphodiesterase-4 inhibitor with antiinflammatory effects that target bronchoconstriction, mucus hypersecretion, and airway remodeling associated with COPD.- Esraa M Mosalam, .et al. , Int J Mol Sci, 2025, Mar 28;26(7):3108 PMID: 40243772
-
PDE Inhibitor
Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency Virus-1 Tat-Mediated activation of microglial cells.- Gadah Ali Alshahrany, .et al. , Pharmaceuticals (Basel), 2026, Jun 28;19(7):1004 PMID: 42515688
-
PDE4 Inhibitor
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.- Tomoaki Higuchi, .et al. , Sci Rep, 2023, Nov 8;13(1):19378 PMID: 37938601
- Higuchi T, .et al. , Research Square, 2023, Mar 02
-
PDE5 inhibitor
Sildenafil, one of the selective phosphodiesterase-5 (PDE5) inhibitors(IC50= 5.22 nM), is considered the best treatment for erectile dysfunction.- Yizhu Yao, .et al. , Phytomedicine, 2024, Nov:134:155976 PMID: 39265445
- Michel R. Corboz, .et al. , Eur J Pharmacol, 2022, 916: 174484 PMID: 34508752
-
PDE3 inhibitor
Cilostazol is a selective inhibitor of 3-type phosphodiesterase (PDE3) with therapeutic focus on cAMP. -
PDE inhibitor
Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. -
PDE4 inhibitor
Hesperetin, a selective phosphodiesterase (PDE)4 inhibitor, is present in the traditional Chinese medicine, ?€?Chen Pi.?€? Hesperetin is a citrus flavonoid that has been reported to lower plasma cholesterol. Hesperetin reduces the transcription of ACAT-2 mRNA in Hep-G2 cells and reduces ApoB protein synthesis in a dose-dependent manner. It also is a potential therapy for carcinoid cancer. -
PDE4 inhibitor
Luteolin is a PDE4 inhibitor, phosphodiesterase inhibitor, and an interleukin 6 inhibitor, affecting xylazine/ketamine-induced anesthesia in mice. Luteolin acts as a monoamine transporter activator, and is one of the few chemicals demonstrated to possess this property. -
PDE3 inhibitor
Milrinone(Primacor) is a a potent and selective phosphodiesterase 3 inhibitor with an IC50 of 0.42 μM for the inhibition of FIII PDE -
PDE inhibitor
Pimobendan (Vetmedin) is a calcium sensitizer with positive inotropic and vasodilator effects. It is also a selective inhibitor of phosphodiesterase III (PDE3). -
PDE4 inhibitor
(S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells. -
PDE5 inhibitor
Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM. -
PDE-5 Inhibitor
Vardenafil is a PDE5 inhibitor used for treating erectile dysfunction. -
Adenosine deaminase inhibitor
EHNA hydrochloride is a specific inhibitor of adenosine deaminase, prevents dAdo degradation and increases mitochondrial dATP levels in fibroblasts. -
PDE9 inhibitor
BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1. -
PDE7/GSK3 inhibitor
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. -
picomolar PDE1 inhibitor
ITI-214 (free base) is a picomolar PDE1 inhibitor with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters, and ion channels, exhibits potent PDE1 inhibitory activity (Ki = 58 pM). -
PDEδ inhibitor
Deltasonamide 2 is a competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM. -
PDEδ inhibitor
Deltasonamide 2 TFA is competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM. -
Autotaxin Inhibitor IV
HA155, also known as Autotaxin Inhibitor IV, is a boronic acid-based compound that inhibits autotaxin (IC50 = 5.7 nM) by selectively binding to its catalytic threonine. -
enpp-1 inhibitor
Enpp-1-IN-1 is a Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitor extracted from patent WO2019046778, Example 55. -
PDE inhibitor
ICI 153110 is an orally active phosphodiesterase inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure. -
PDE10A inhibitor
Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier. -
PDE8 inhibitor
PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC50s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively. -
PDE-5 inhibitor
Mirodenafil(SK3530) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. -
PDE3 inhibitor
Saterinone hydrochloride is a phosphodiesterase III (PDE III) inhibitor. -
PDE4 inhibitor
Lotamilast (RVT-501; E6005) is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 2.8 nM. -
PDE Inhibitor
Theophylline, a potent phosphodiesterase (PDE) inhibitor, primarily targets PDE3, leading to relaxation of airway smooth muscle and enhanced bronchodilation. This compound also functions as an adenosine receptor antagonist and exhibits anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation into the nucleus. Additionally, Theophylline has been shown to induce apoptosis in certain cell types. Its applications are particularly relevant in the research of asthma and chronic obstructive pulmonary disease (COPD). -
PDE4/NF-κB inhibitor
Sappanone A is an orally active homoisoflavone isolated from Caesalpinia sappan L., exhibiting notable anti-inflammatory and antioxidant properties. It functions as an inhibitor of phosphodiesterase 4 (PDE4) and NF-κB, key regulators of inflammatory signaling. Additionally, Sappanone A activates the Nrf2 pathway, leading to increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1). Sappanone A also inhibits RANKL-induced osteoclastogenesis, suggesting potential benefits in bone metabolism disorders. With its multifaceted bioactivity, Sappanone A holds significant promise for research in inflammation-related diseases, cardiovascular conditions, and bone health. -
PDE Inhibitor
Theophylline sodium acetate functions as a potent phosphodiesterase (PDE) inhibitor, specifically targeting PDE3 to promote the relaxation of airway smooth muscle. It also acts as an adenosine receptor antagonist and histone deacetylase (HDAC) activator, contributing to its anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation to the nucleus. Additionally, Theophylline sodium acetate is known to induce apoptosis, making it a valuable reagent for research on asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 Inhibitor
PDE4-IN-10 is a selective phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 of 7.01 μM for the PDE4B isoform. This compound demonstrates significant biological activity by inhibiting TNF-α production and exhibits microsomal stability, making it suitable for various in vitro applications. PDE4-IN-10 is a valuable tool for research aimed at understanding inflammatory processes and developing therapeutic strategies for related diseases. -
PDE Inhibitor
Theophylline L-lysine is a soluble derivative of Theophylline that primarily acts as a phosphodiesterase (PDE) inhibitor. It effectively inhibits PDE3 activity, which leads to relaxation of airway smooth muscle and exhibits anti-inflammatory properties through the enhancement of IL-10 levels and the inhibition of NF-κB nuclear translocation. Additionally, Theophylline L-lysine induces apoptosis, making it a valuable compound for research applications in asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 Inhibitor
AN-2898 is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 0.027 μM, demonstrating significant potency over other phosphodiesterase enzymes, including PDE1A, PDE2A, and PDE3A. It effectively inhibits PDE4 subtypes such as PDE4B1, PDE4A1A, and PDE4D2. AN-2898 significantly reduces the production of pro-inflammatory cytokines including TNF-α, IL-2, IFN-γ, IL-5, and IL-10, making it a valuable reagent for research applications in mild to moderate atopic dermatitis and psoriasis. -
PDE4 Inhibitor
LY2775240 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating significant inhibitory activity against PDE4A, PDE4B, and PDE4D with IC₅₀ values of 0.09 nM and 0.14 nM for the latter two, as well as an IC₅₀ of 2.4 nM for PDE4C. This compound effectively reduces TNFα production during immune activation, making it valuable for studies investigating inflammatory conditions. LY2775240 is particularly relevant for research focused on psoriasis, as evidenced by its efficacy in lowering TNFα levels in rodent and cynomolgus monkey models. -
PDE4 Inhibitor
ASP9831 is an orally active phosphodiesterase type 4 (PDE4) inhibitor. It effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α) production, demonstrating notable anti-inflammatory properties. This compound is valuable for research applications centered on fatty liver disease and related inflammatory conditions. -
PDE4 Inhibitor
Revamilast is an orally active phosphodiesterase-4 (PDE4) inhibitor with a reported IC50 of 3 nM. This compound effectively inhibits the production of tumor necrosis factor-alpha (TNF-α), making it a valuable tool for research into inflammatory conditions. Applications include studies related to rheumatoid arthritis, plaque psoriasis, asthma, and other related inflammatory diseases.
